Please read and agree to the terms and conditions of this site.
@m2bio 10 months ago
#HappyYouthDay South Africa🤗Looking forward to another spectacular day. Great to see some new shareholders joining the M2Bio journey. PR today. Go $MRES #drugdiscovery #artificialintelligence #machinelearning #ScienceInAction #medicine #health #stocks #investing https://t.co/vGCNgGlUbl
@xconomy.com 3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com 3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com 3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com 3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com 3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com 3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@SpirosMargaris 3 years ago
COVID-19 might be bitter #medicine for what ails #AI #investing https://buff.ly/2XA5Fk9 #fintech #VC #startup #ArtificiallIntelligence #MachineLearning #DeepLearning #covid19 #coronavirus @SiliconANGLE @Paula_Piccard @andi_staub @SabineVdL @psb_dc @Fisher85M @ipfconline1 https://t.co/7dcYVuXtNq
@xconomy.com 3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com 4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com 4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com 4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone